We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Geoffrey Oxnard MD

Geoffrey R Oxnard MD

Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Dana-Farber Cancer Institute, Boston, Massachusetts

Dr. Geoff Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to use comprehensive genomics to identify novel molecular alterations and study their clinical biology, towards the development of new clinical trials using genotype-directed therapies.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. His research was recognized with a Young Investigator Award in 2010 and a Career Development Award in 2012, both from the Conquer Cancer Foundation of ASCO.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.



1. Serve(d) as Consultant for: Astra-Zeneca

2. Serve(d) as Consultant for: Astellas

3. Serve(d) as Consultant for: Boehringer-Ingelheim

4. Serve(d) as Consultant for: Genentech

5. Serve(d) as Consultant for: Novartis

6. Receive(d) honoraria for talks from: Astra-Zeneca

7. Receive(d) honoraria for talks from: Boehringer-Ingelheim

8. Receive(d) honoraria for talks from: Chugai